ERBB2 and triple-negative breast carcinoma: Triple negative breast cancer (TNBC) is the most aggressive and has the worst prognosis because it does not respond to hormonal therapy or drugs that target the human epidermal growth factor receptor 2 (HER2) protein and has an overall 5-year survival rate of ca. 12% [2,3].